Which drug first? new study aims to improve breast cancer treatment order
NCT ID NCT07368543
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at two powerful drugs, sacituzumab govitecan (SG) and trastuzumab deruxtecan (T-DXd), for people with a certain type of advanced breast cancer (HER2-low/TROP2-high). The goal is to find out which drug works best when given first and how to switch if the first stops working. About 216 adults will take part, and researchers will track how long the cancer is controlled and look for markers that predict success.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HER2 IHC 1+ BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a High-Fiber diet shield the gut during breast cancer therapy?
- Can a Two-Drug attack shrink Hard-to-Treat breast cancer?
- Can mapping tumor DNA unlock personalized breast cancer care?
- Can a Two-Pronged antibody boost Chemo's power against a tough breast cancer?
- Can a new drug rally the immune system against Hard-to-Treat cancers?
- Could a personal coach at home boost energy for cancer patients?